Pipeline Review on Traumatic Brain Injuries – H2 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Traumatic Brain Injury – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer’s disease and coordination problems.

The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 13, 2, 96 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. (Read more…) Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)

Reasons to Buy

1. Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
2. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
3. Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
4. Classify potential new clients or partners in the target demographic.
5. Develop tactical initiatives by understanding the focus areas of leading companies.
6. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
7. Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
8. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
9. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Overview
• Therapeutics Development
• Therapeutics Assessment
• Companies Involved in Therapeutics Development
• Drug Profiles
• Dormant Projects
• Discontinued Products
• Product Development Milestones
• Appendix

Companies Mentioned

• Abliva AB
• Acelerox LLC
• AegisCN LLC
• AivoCode LLP
• ALSP Inc
• AlzeCure Pharma AB
• AMAG Pharmaceuticals Inc
• American CryoStem Corp
• Anagin Inc
• Anida Pharma Inc
• Annovis Bio Inc
• AntiRadical Therapeutics LLC
• Anvyl LLC
• Aptinyx Inc
• Astrocyte Pharmaceuticals Inc
• Athersys Inc
• Avanir Pharmaceuticals Inc
• Bessor Pharma LLC
• Beyond Barriers Therapeutics Inc
• Biogen Inc
• BioIncept LLC
• Bioquark Inc
• Brain-Gen LLC
• CalciMedica Inc
• CavoGene LifeSciences
• CellCure
• Cellvation Inc
• CereSpir Inc
• Chimerix Inc
• Chrysalis BioTherapeutics Inc
• Cognosci Inc
• Complement Pharma BV
• DeckTherapeutics Inc
• Deha Pharmaceutical LLC
• Eagle Pharmaceuticals Inc
• Eisai Co Ltd
• And Many More Companies!

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/96b1r3

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900